Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 456906 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs BI 456906 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 20 Feb 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2017 Planned End Date changed from 4 Jun 2018 to 13 Feb 2018.